Consensus Statement Print a PDF References Figures & Tables Supplements

MOSCA et al., Guide to CVD Prevention in Women
JACC 2004; 43:900-21

Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women

References

  1. Mosca L, Grundy SM, Judelson D, et al. Guide to preventive cardiology for women. AHA/ACC scientific statement, consensus panel statement. Circulation 1999;99:2480–4.
  2. American Heart Association. Heart disease and stroke statistics—2003 update. Dallas, TX: American Heart Association, 2002.
  3. Yusuf S, Reddy S, Ounpuu S, et al. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 2001;104:2746–53.
  4. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. Writing group for the Women’s Health Initiative investigators. JAMA 2002;288:321–33. Summary for patients in: CMAJ 2002;167:377–8, and J Fam Pract 2002;51:821.
  5. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. Women’s Health Initiative investigators. N Engl J Med 2003;349:523–34.
  6. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women’s Health Initiative: a randomized trial. Women’s Health Initiative investigators. JAMA 2003;289:2673–84.
  7. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) research group. JAMA 1998;280:605–13.
  8. Meinert CL, Gilpin AK, Unalp A, et al. Gender representation in trials. Control Clin Trials 2000;21:462–75.
  9. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486–97.
  10. Smith S, Blair S, Bonow R, et al. AHA/ACC scientific statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 2001;104:1577–9.
  11. Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002;106: 388–91.
  12. Gibbons R, Smith S, Antman E. American College of Cardiology/American Heart Association Clinical Practice Guidelines: Part I: where do they come from? Circulation 2003;107:2979–86.
  13. Benjamin EJ, Smith SC, Cooper RS, et al. Task Force #1–magnitude of the prevention problem: opportunities and challenges. 33rd Bethesda Conference. J Am Coll Cardiol 2002;40:588–603.
  14. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Scientific statement of the American Heart Association Nutrition Committee. Circulation 2002;106:2747–57. Erratum in: Circulation 2003;107:512.
  15. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560–72. Erratum in: JAMA 2003;290:197.
  16. American Diabetes Association. Implications of the diabetes control and complications trial. Diabetes Care 2003;26 Suppl 1:S25–7.
  17. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type II diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393–403.
  18. American College of Obstetricians and Gynecologists. Response to Women’s Health Initative Study Results by the American College of Obstetricians and Gynecologists. June 3, 2003. Available at http://www.acog.com/member_access/ misc/whiResponse.cfm.
  19. The North American Menopause Society. Estrogen and progestogen use in peri- and postmenopausal women: September 2003 position statement of The North American Menopause Society. Menopause 2003;10:497–506.
  20. D’Agostino RB Sr, Grundy S, Sullivan LM, et al. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. CHD Risk Prediction Group. JAMA 2001;286:180–7.
  21. Grundy SM, D’Agostino Sr RB, Mosca L. Cardiovascular risk assessment based on US cohort studies: findings from a National Heart, Lung, and Blood institute workshop. Circulation 2001;104:491–6.
  22. Mosca L, Collins P, Herrington DM, et al. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 2001;104:499–503.

© 2004 by the American College of Cardiology

Back to Top | | Copyright © 2008 American College of Cardiology
Heart House | 2400 N Street, NW | Washington, DC 20037